Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NAPRT CRISPR/Cas9 KO Plasmid (h): sc-406144
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NAPRT CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the NAPRT genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NAPRT Antibody (B-8): sc-398404
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NAPRT CRISPR/Cas9 KO Plasmid (h) | sc-406144 | 20 µg | $397.00 |
Overview
NAPRT (nicotinate phosphoribosyltransferase) is a key enzyme in NAD biosynthesis that catalyzes conversion of nicotinic acid to nicotinic acid mononucleotide, supporting the Preiss–Handler pathway. By sustaining cellular NAD pools, NAPRT influences redox homeostasis and the activity of NAD-dependent enzymes involved in metabolism, stress responses, and DNA repair. Altered NAPRT expression or activity has been associated with metabolic rewiring and NAD salvage dependencies observed across multiple disease contexts, including cancer and inflammatory conditions. As a result, NAPRT is frequently studied in pathways governing energy metabolism, mitochondrial function, and cellular resilience to genotoxic or oxidative stress.
NAPRT CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the NAPRT gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NAPRT together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NAPRT open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NAPRT protein expression.
This CRISPR knockout system enables efficient generation of NAPRT-deficient cell models for investigation of NAPRT signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting NAPRT exon(s) critical for NAPRT function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple NAPRT genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by NAPRT CRISPR/Cas9 KO Plasmid (h) and NAPRT CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NAPRT locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by NAPRT HDR Plasmid (h) and NAPRT HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NAPRT homology arms to support homology-directed repair at defined NAPRT target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.